Hi Thoracic Colleagues!
We have started a few patients on taletrectinib recently and have been monitoring uric acid per the PI.
I looked at the protocol for the TRUST trials and could not find much guidance as to when you would consider initiating urate-lowering therapy.
CTCAE grading of hyperuricemia is not very helpful and only distinguishes between elevated uric acid without symptoms (Grade 1) and with symptoms (Grade 3).
At what uric acid level would you consider starting therapy in an asymptomatic patient?
My patient's level yesterday was 8.3 (for a female, > 6 is elevated).
I was thinking > 10 (she is otherwise pretty healthy and does not have kidney problems). Is this too lax?
Thanks in advance and Happy Friday!
------------------------------
Stefanie Houseknecht PharmD
Clinical Pharmacy Specialist
The Johns Hopkins Hospital
Baltimore MD
------------------------------